Form 4 for JBIO Jade Biosciences, Inc.
Accepted 2021-07-06 00:00:00 ET · period of report 2021-07-01 · accession 0001104659-21-089437 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2021-07-06 | 2021-07-02 | JBIO | Katabi Maha | Dir, 10% | C - Cnv Deriv | — | +3.40M | 3.40M | New | — |
| DI | 2021-07-06 | 2021-07-02 | JBIO | Katabi Maha | Dir, 10% | P - Purchase | $14.00 | +357.1K | 3.76M | +10% | +$5.00M |
| D | 2021-07-06 | 2021-07-01 | JBIO | Katabi Maha | Dir, 10% | A - Grant | $11.15 | +2,467 | 2,467 | New | +$27.5K |
| DI | 2021-07-06 | 2021-07-02 | JBIO | Katabi Maha | Dir, 10% | C - Cnv Deriv | — | -10.57M | 0 | -100% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-07-02 | C | A | 3,401,544 | — | 3,401,544 | I By Sofinnova Venture Partners X, L.P. | — | — | (F1) Each share of Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.1060103 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. (F2) The shares are held directly by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy and Maha Katabi are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his or her proportionate pecuniary interest therein. |
| 2 | Common | Common Stock | 2021-07-02 | P | A | 357,142 | $14.00 | 3,758,686 | I By Sofinnova Venture Partners X, L.P. | — | — | (F2) The shares are held directly by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy and Maha Katabi are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his or her proportionate pecuniary interest therein. |
| 3 | Derivative | Stock Option (Right to Buy) | 2021-07-01 | A | A | 2,467 | $11.15 | 2,467 | D By Sofinnova Venture Parnters X, L.P. | $19.41 · — to 2031-06-30 | 2,467 Common Stock | (F2) The shares are held directly by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy and Maha Katabi are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his or her proportionate pecuniary interest therein. (F3) This option was awarded in lieu of cash compensation pursuant to the Issuer's Non-Employee Director Compensation Policy. The shares underlying such option shall vest and become exercisable in two equal installments, with the first installment vesting on September 30, 2021 and the second installment vesting on December 31, 2021. |
| 4 | Derivative | Series A Preferred Stock | 2021-07-02 | C | D | 10,565,238 | — | 0 | I | — · — to — | 3,401,544 Common Stock | (F1) Each share of Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.1060103 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. |